MERZ

31.1.2020 09:04:13 CET | Business Wire | Press release

Merz Aesthetics Presents Data at the IMCAS World Congress 2020

Merz, a global leader in medical aesthetics, announced today that data on the Merz Aesthetics product portfolio, including Belotero^® , Cellfina^® and Radiesse^® will be featured in oral and poster presentations at the 2020 International Master Course on Aging Science (IMCAS) World Congress, to be held from 30 January to 1 February 2020 in Paris, France.

“This meeting provides a platform for Merz Aesthetics to not only foster education and continuous training but also, to engage in thoughtful industry conversations while connecting with medical aesthetics physicians and fellow industry leaders from around the world,” said Bob Rhatigan, CEO of Merz Aesthetics. “We are grateful that our heritage and innovation in this space allows us to partner with world-renowned medical aesthetic experts, to share research on the diversified Merz Aesthetics product portfolio at the IMCAS World Congress.”

In addition to the poster presentations listed below, Merz Aesthetics is sponsoring the symposium event “Facial Rejuvenation: Interactive Sessions to Level-Up Your Injection Skills”, to be held on Saturday, 1 February at 10.30h – 12.30h, Room Amphi Bleu . The session will be opened by Bob Rhatigan, CEO of Merz Aesthetics and will include treatment insights from four international expert speakers:

Dr. Tatjana Pavicic – Dermatologist, Germany
Dr. Kate Goldie – Aesthetic Physician, United Kingdom
Prof. Yana Yutskovskaya – Dermatologist, Russia
Dr. Jani van Loghem – Aesthetic Physician, Netherlands

Oral Presentations

Independent presentations including data on the Merz Aesthetics portfolio:

What’s new in minimally invasive treatments

Update on dermal fillers (99921) – Kate Goldie, MBChB – UK. Thursday, 30 January, 17.54 – 18.06h, Amphi Bleu – Level 2

Body shaping and cellulite

Cellulite and skin laxity (93276). Doris Hexsel, Dermatologist – Brazil. Thursday, 30 January, 10.30 – 10.42h, Amphi Bleu – Level 2
Cellulite treatment update: how dimples, laxity and volume can be effectively treated (98147)¹ . Gabriela Casabona, MD– Spain. Thursday, 30 January, 11.18 – 11.30h, Amphi Bleu – Level 2

Biostimulatory fillers

Biostimulators: how dilution/diffusion interferes with outcome (93391). Gabriela Casabona, MD – Spain. Saturday, 1 February, 16.30 – 16.42, Room 143 - Level 1

E-Poster Presentations

E-Posters will be available for viewing at the Poster Zone on Level 2 , from Thursday, 30 January to Saturday, 1 February 2020 .

Distribution of cohesive polydensified matrix cross-linked hyaluronic acid volumizing gel in ex vivo human skin model. Christina Wollenburg, Jeanette Simon, Dr. Kay Marquardt, Dr. Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany.
Calcium hydroxylapatite microspheres provide organization into unorganized collagen networks leading to improvement of skin attractiveness. Gabriela Casabona, MD – Spain. Dr. Bartosch Nowag, Daniela Schäfer, Davide Greco, Dr. Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany.

BOCOUTURE^® Milestone

This year, Merz is also celebrating the ten-year anniversary of BOCOUTURE^® (incobotulinumtoxin A) in Europe. The botulinum toxin is part of the Merz Aesthetics portfolio and has received approval in 15 countries in Europe within the last ten years. A Booth Talk about “BOCOUTURE^® - 10 Years of a Unique Neurotoxin” with Dr. Thomas Rappl will take place Friday, 31 January, 16.00, Booth N° P251 .

About Merz

Merz is a global, diversified healthcare company based in Frankfurt, Germany. Privately-held for more than 111 years, the company operates in the areas of aesthetics, therapeutics and consumer care and is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In fiscal year 2018/19, Merz generated revenue of EUR 1,094 million; the company has a total workforce of 3,213 employees worldwide and a direct presence in 28 countries. More information is available at www.merz.com .

¹ Merz supported Investigator Initiated Trials

View source version on businesswire.com: https://www.businesswire.com/news/home/20200131005133/en/

About Business Wire

Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom